Autobahn Therapeutics
PrivateLast Round
Series C
Jul 24, 2024
Total Funding Raised
$208.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Autobahn Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series C round in July 2024.
Autobahn Therapeutics is a biotechnology company developing regenerative medicines and brain-targeting chemistry aimed at treating central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Autobahn Therapeutics Comparables
Compare Autobahn Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Delix Therapeutics | 89% | |
| Engrail Therapeutics | 84% | |
| Gilgamesh Pharmaceuticals | 79% |
For institutional investors. Book with your work email.
Autobahn Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 24, 2024 | ||||
| Series B Extension | Sep 8, 2022 | ||||
| Series B | Jun 9, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Autobahn Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Series C |
| S32 | Series B Extension, Series C, Series B |
| TD Securities | Series B Extension, Series B |
| Blue Owl Capital | Series B Extension, Series C, Series B |
| Monograph Capital | Series C |
| Invus Opportunities | Series B Extension |
| ARCH Venture Partners | Series C, Series B Extension, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 79% MoM.
- Jul 8, 2025
Will present at Evercore's Emerging Private Biotech Conference.
For institutional investors. Book with your work email.
Autobahn Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Autobahn Therapeutics's valuation, stock price, and market status.
Is Autobahn Therapeutics a public or private company?
Autobahn Therapeutics is a private company.
What is the current stock price of Autobahn Therapeutics?
Autobahn Therapeutics is a private company, so its shares have no public market price. Caplight tracks Autobahn Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Autobahn Therapeutics worth (valuation)?
Valuation information for Autobahn Therapeutics is not publicly available.
Can I buy Autobahn Therapeutics stock?
Autobahn Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Autobahn Therapeutics's last funding round?
Autobahn Therapeutics's most recent funding round was Series C on July 24, 2024.
Who are the main investors in Autobahn Therapeutics?
Key investors in Autobahn Therapeutics include Newpath Partners, TD Securities, Blue Owl Capital, ARCH Venture Partners.
Will Autobahn Therapeutics IPO soon?
No public IPO plans have been announced for Autobahn Therapeutics.
How can I track Autobahn Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Autobahn Therapeutics's shares on secondary markets.